An international research team engineered Saccharomyces boulardii to remove virulence features and demonstrated reduced infection risk in animal models, addressing safety concerns for probiotic use in immunocompromised patients. The study, published in Communications Biology, reports that the edited strain is less likely to cause bloodstream infections while retaining probiotic function in tested models. Authors framed the modification as a step toward enabling broader probiotic deployment in vulnerable populations (elderly, NICU infants, immunosuppressed). The paper calls for additional translational work—including efficacy and regulatory pathways—before clinical use, and highlights genomic safeguards as a strategy to mitigate probiotic‑linked adverse events.